🇺🇸 FDA
Patent

US 8450299

Methods of hormonal treatment utilizing ascending-dose extended cycle regimens

granted A61KA61K31/56A61K31/567

Quick answer

US patent 8450299 (Methods of hormonal treatment utilizing ascending-dose extended cycle regimens) held by Teva Womans's Health, Inc. expires Mon May 23 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Teva Womans's Health, Inc.
Grant date
Tue May 28 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 23 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/56, A61K31/567, A61K31/57, A61P